Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC economic evaluation of treatments for multiple myeloma presented at Health Economics conference

Published: 15 August 2011
SHTAC present findings at HESG

An economic evaluation of first-line treatments for people with multiple myeloma was presented at the annual Health Economists’ Study Group (HESG) conference.

Dr Keith Cooper presented a poster entitled, ‘Cost-effectiveness of first-line treatments for multiple myeloma' at the Health Economists' Study Group (HESG) conference on 30th June 2011 at the University of Bangor. The poster summarised a cost-utility model that was used to compare the cost-effectiveness estimates of bortezomib and thalidomide as first-line treatments for multiple myeloma in people who were ineligible for intensive treatment regimes. Multiple myeloma is the second most common haematological cancer in the UK but remains an incurable disease. There are several available first-line therapies available that aim to extend the length and quality of life by alleviating symptoms, controlling disease and minimising adverse effects. The economic evaluation was conducted as part of an appraisal of the two drugs by the National Institute for Health and Clinical Excellence (NICE). The full research report is available on the NICE website, and will also be published in the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme monograph series in the near future.

Privacy Settings